Ozempic Compassionate Use and Expanded Access: A Complete 2026 Guide

What "Compassionate Use" Actually Means, and Why Ozempic Doesn't Qualify

Compassionate use, formally called expanded access by the FDA, is a regulatory pathway that allows patients to use an investigational drug outside of a clinical trial when no comparable alternative exists. The FDA's expanded access regulations (21 CFR Part 312, Subpart I) are explicit: the drug must not be approved for the condition being treated, or the patient must have a serious or life-threatening condition with no satisfactory alternatives.

Ozempic received FDA approval for type 2 diabetes management in adults on December 5, 2017. FDA approval records confirm semaglutide 0.5 mg and 1.0 mg injection. Because the drug is approved and commercially available, there is no legal or regulatory basis for a compassionate use or expanded access application.

The Approved Indications for Ozempic in 2026

Ozempic carries two approved indications as of 2026. The first is glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. The second, added via label update, is reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on the SUSTAIN-6 trial (N=3,297), which showed a 26% relative risk reduction in the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke at 2.1 years [1].

Weight management is approved only for Wegovy (semaglutide 2.4 mg), not Ozempic. Prescribers who write Ozempic off-label for obesity are doing so outside the labeled indication. Off-label prescribing is legal, but it changes insurance coverage calculations and patient assistance eligibility.

What Expanded Access Actually Requires

The FDA expanded access guidance document (May 2023) specifies three criteria: the patient has a serious or immediately life-threatening disease, the potential benefit justifies the risk, and providing the drug will not interfere with clinical investigation. None of these criteria produces a pathway for Ozempic because a commercially available, pharmacist-dispensable product already exists. A physician cannot submit a single-patient IND for semaglutide in a diabetes or weight-loss context for this reason.

Novo Nordisk's Patient Assistance Program: The Real Access Route

For uninsured or underinsured patients, the closest functional equivalent to "compassionate access" is the Novo Nordisk Patient Assistance Program (PAP), administered through NovoCare. This program provides Ozempic at no cost to qualifying patients.

Eligibility Criteria for the Novo Nordisk PAP

Income limits are set as a percentage of the Federal Poverty Level (FPL). For most program tiers in 2025 to 2026, eligibility extends to patients at or below 400% FPL, roughly $60,240 for an individual or $124,800 for a family of four using 2025 HHS poverty guidelines [2]. Patients must also:

• Have a valid prescription from a licensed U.S. Prescriber
• Be residents of the United States or U.S. Territories
• Lack coverage through a federal or state insurance program (Medicare Part D, Medicaid, or CHIP disqualify applicants)
• Have no adequate private insurance coverage for the drug

The program delivers medication by mail directly to the prescriber's office or, in some cases, to the patient's home. Processing times run 2 to 4 weeks for initial applications. Patients should apply before their current supply runs out.

How to Apply Step by Step

1. Ask your prescriber to complete the provider section of the NovoCare PAP enrollment form.
2. Submit proof of income (most recent federal tax return or three months of pay stubs).
3. Include a copy of any insurance denial letters if applicable.
4. Fax or mail the completed packet to NovoCare's processing center; the address is on the NovoCare website.
5. Expect a letter of approval or denial within 10 to 15 business days.

Re-enrollment is required every 12 months. The ADA's 2024 Standards of Care note that "financial barriers to medication adherence are among the most common reasons patients fail to achieve glycemic targets," and recommend that clinicians screen for cost-related nonadherence at every visit [3].

The NovoCare Savings Card: Fastest Discount for Commercially Insured Patients

Patients with commercial (private) insurance who do not qualify for the PAP may use the NovoCare Savings Card, which reduces out-of-pocket cost to as low as $99 per month for a 1-month supply or $150 for a 3-month supply, subject to program terms. The card is not valid for patients using Medicare, Medicaid, or any other government-funded insurance.

How the Savings Card Works

The card functions as a secondary payer. At the pharmacy, the patient presents both their insurance card and the savings card. Insurance processes first, then the savings card offsets the remaining patient portion up to the program maximum. Novo Nordisk's published terms cap total savings at a set annual maximum, which has historically been around $3,600, $4,800 per year depending on the program year.

Card activation is free and takes about 10 minutes online. Patients must provide their date of birth, zip code, and prescriber information. There is no income verification for the savings card, which distinguishes it from the PAP.

The HealthRX access decision framework below summarizes which program fits each patient profile:

| Patient Profile | Best Access Route | |---|---| | Uninsured, income <400% FPL | Novo Nordisk PAP (free drug) | | Commercially insured, high copay | NovoCare Savings Card ($99/mo) | | Medicare Part D gap | State SPAP or Extra Help/LIS | | Medicaid denied coverage | State prior authorization appeal | | No diabetes diagnosis, weight loss only | Wegovy PAP or Ozempic off-label appeal |

Medicare and Medicaid Coverage in 2026

Medicare Part D covers Ozempic for its approved diabetes indication. Coverage depends on the specific plan formulary; most Part D plans place semaglutide injectable on Tier 3 or Tier 4, producing copays of $40, $120 per month in the initial coverage phase. Once a patient enters the catastrophic coverage phase (after $2,000 out-of-pocket in 2025 due to the Inflation Reduction Act changes), cost-sharing drops to 5% or a small copay [4].

Extra Help (Low-Income Subsidy)

Patients with Medicare Part D who meet income thresholds may qualify for Extra Help, the Social Security Administration's low-income subsidy program. Extra Help caps drug costs at roughly $4.50 for generics and $11.20 for brand drugs per fill in 2025 [5]. Applications are submitted directly to the Social Security Administration or through a State Pharmaceutical Assistance Program (SPAP).

Medicaid Coverage Variability

Medicaid formulary decisions vary by state. Most state Medicaid programs cover GLP-1 receptor agonists for type 2 diabetes but may require step therapy through metformin and at least one other agent before approving semaglutide. A 2023 analysis published in JAMA Internal Medicine found that among state Medicaid programs, 42 of 50 covered at least one GLP-1 receptor agonist, but prior authorization was required in 38 of those 42 states [6].

Prior Authorization: How to Get It Approved

Insurance denials for Ozempic typically cite "step therapy not completed" or "not medically necessary." Both are appealable.

Building the Clinical Case

A strong prior authorization (PA) request should include:

• Current HbA1c value and trend over the prior 6 to 12 months
• Documentation of metformin trial (minimum 90 days at maximally tolerated dose)
• Documentation of at least one sulfonylurea or SGLT-2 inhibitor trial, if applicable
• Body weight and BMI
• Cardiovascular risk factors or confirmed ASCVD, because the SUSTAIN-6 data [1] provide the strongest clinical argument for semaglutide specifically over other GLP-1 agents

The ADA 2024 Standards of Care (Section 9, Pharmacologic Approaches to Glycemic Treatment) recommend GLP-1 receptor agonists as preferred add-on therapy in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [3]. Including this guideline language verbatim in the PA letter strengthens the case.

The Appeals Process

If the PA is denied, the patient has two appeal tiers: internal review by the insurer and external independent review. Under the Affordable Care Act, insurers must provide written denial reasons and allow at least 180 days to file an internal appeal. External review decisions are binding on the insurer in most states. A 2022 study in Health Affairs found that patients who pursued external appeals for specialty medications won reversal in approximately 39% of cases [7].

Compounded Semaglutide: The 2024 to 2026 Status Change

During the FDA drug shortage period (2022 to 2024), compounding pharmacies produced semaglutide injectable products legally under 503A and 503B provisions. Patients accessed these at $100, $300 per month, far below brand pricing.

FDA Removed Semaglutide from the Shortage List

The FDA announced the removal of semaglutide from the drug shortage list in February 2024 and confirmed the transition period ended October 22, 2024 for 503B outsourcing facilities and March 19, 2025 for 503A pharmacies [8]. After those dates, most compounding of semaglutide base became impermissible under federal law, except for documented individual patient allergies or other specific clinical needs requiring a customized formulation.

What This Means for Patients in 2026

Patients who were using compounded semaglutide products should transition to an FDA-approved product. The FDA's compounding oversight page outlines the current enforcement posture. Patients receiving compounded products from telehealth companies after the prohibition dates may be receiving a product of unverified potency, sterility, and dosing accuracy. The FDA has issued warning letters to several compounding facilities for subpotent or mislabeled semaglutide products [8].

HSA and FSA Use for Ozempic

Ozempic prescribed for type 2 diabetes is a qualified medical expense under IRS Publication 502 guidance on medical and dental expenses, making it eligible for payment from a Health Savings Account (HSA) or Flexible Spending Account (FSA) [9].

Specifics on Eligible Use

The eligibility rule ties to the medical purpose of the prescription, not the drug itself. A prescription for Ozempic written for type 2 diabetes qualifies. A prescription written off-label for weight loss without a diabetes diagnosis occupies a grayer area, though most plan administrators and HSA custodians will process the expense as long as a licensed prescriber wrote the prescription and it was filled at a licensed pharmacy.

FSA funds are subject to the use-it-or-lose-it rule for most plan years, though a carryover of up to $640 (2024 IRS limit) is allowed if the employer plan includes a carryover provision [9]. HSA funds roll over indefinitely and can be invested once the account balance exceeds the plan's investment threshold, making them particularly useful for high-cost chronic medications.

Patients can pay for Ozempic with HSA/FSA funds at the pharmacy point of sale using an HSA/FSA debit card, or they can pay out of pocket and submit receipts for reimbursement. Keep the pharmacy receipt and the Explanation of Benefits from the insurer; both are needed if the IRS audits the HSA withdrawal.

GoodRx, Coupon Programs, and Third-Party Discount Tools

For patients who do not qualify for manufacturer programs and lack adequate insurance, third-party discount platforms represent another cost-reduction option, though savings are smaller than the NovoCare card.

GoodRx prices for Ozempic pens (4-count, 1.34 mL/0.5 mg/dose) have ranged from $850 to $935 depending on pharmacy and geography in 2025. GoodRx coupons typically produce a discount of 5 to 12% off the cash price, bringing the monthly cost to roughly $820, $890. This is meaningful but still high for most patients without insurance.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (CostPlusDrugs.com) does not currently carry branded Ozempic because it is still under patent. The platform lists drugs at manufacturing cost plus a 15% markup and $3 dispensing fee [10], which is significant for generic medications but does not yet apply to semaglutide.

Clinical Rationale: Why Patients Fight for Access to Semaglutide

The clinical evidence supporting semaglutide's efficacy is extensive enough that access barriers have genuine health consequences.

Glycemic Efficacy

In the SUSTAIN-7 trial (N=1,201), semaglutide 1.0 mg reduced HbA1c by 1.8 percentage points from baseline at 40 weeks, compared with 1.4 percentage points for dulaglutide 1.5 mg (P<0.001) [11]. Semaglutide also produced 6.5 kg greater weight loss than dulaglutide at 40 weeks.

Cardiovascular Outcomes

SUSTAIN-6 (N=3,297) demonstrated that semaglutide reduced MACE (major adverse cardiovascular events) by 26% versus placebo over 2.1 years (HR 0.74; 95% CI 0.58 to 0.95; P<0.001) [1]. The SELECT trial (N=17,604) extended this finding to semaglutide 2.4 mg in patients without diabetes, showing a 20% reduction in MACE [12], though that indication belongs to Wegovy, not Ozempic.

Kidney Protection

FLOW (N=3,533) was the first dedicated renal outcomes trial for semaglutide in type 2 diabetes. Published in the NEJM in May 2024, it showed semaglutide 1.0 mg reduced the composite kidney endpoint by 24% versus placebo (HR 0.76; 95% CI 0.66 to 0.88; P<0.001) [13]. This led the FDA to approve a new labeling addition for reducing kidney disease progression in adults with type 2 diabetes and chronic kidney disease in 2024. Patients with CKD and type 2 diabetes now have a particularly strong clinical argument for semaglutide-specific prior authorization.

Biosimilars on the Horizon

No FDA-approved semaglutide biosimilar exists as of early 2026. Ozempic's U.S. Patent exclusivity, covering the semaglutide molecule and the delivery device, is projected to expire no earlier than 2032 for the core compound patent. Secondary formulation and method-of-use patents may extend effective market exclusivity further.

The FDA's biosimilar development guidance outlines the approval pathway for follow-on biologics. Several manufacturers, including Sun Pharmaceutical and Biocon, have announced preclinical or early-phase semaglutide biosimilar programs, but none has filed a Biologics License Application with the FDA as of this writing [14].

When biosimilars do reach the market, historical GLP-1 market data suggest a 40 to 60% price reduction within 24 months of the first biosimilar approval, based on the pattern seen with insulin glargine after Basaglar's 2015 approval [15].